Abstract
Background Achieving adequate mass drug administration (MDA) coverage for lymphatic filariasis is challenging. We sought to improve stakeholder engagement in MDA planning and improve subsequent MDA coverage through a series of microplanning workshops.
Methodology/Principal Findings Prior to the 2018 MDA, Haiti’s Ministry of Public Health and Population (MSPP) and partners conducted 10 stakeholder microplanning workshops in metropolitan Port-au-Prince. The objectives of the workshops were to identify and address gaps in geographic coverage of supervision areas (SAs); review past MDA performance and propose strategies to improve access to MDA; and review roles and responsibilities of MDA personnel, through increased stakeholder engagement. Retrospective pre-testing was used to assess the effectiveness of the workshops. Participants used a 5-point scale to rank their understanding of past performance, SA boundaries, roles and responsibilities, and their perceived engagement by MSPP. Participants simultaneously ranked their previous year’s attitudes and their attitudes following the 2-day microplanning workshop. Changes in pre- and post-scores were analyzed using Wilcoxon-signed rank tests. A total of 356 stakeholders across five communes participated in the workshops. Participants conducted various planning activities including revising SA boundaries to ensure full geographic reach of MDA, proposing or validating social mobilization strategies, and proposing other MDA improvements. Compared with previous year rankings, the workshops increased participant understanding of past performance by 1.34 points (standard deviation [SD]=1.05, p<0.001); SA boundaries by 1.14 points (SD=1.30; p<0.001); their roles and responsibilities by 0.71 points (SD=0.95, p-<0.001); and sense of engagement by 1.03 points (SD=1.08, p<0.001). Additionally, drug coverage increased in all five communes during the 2018 MDA.
Conclusions/Significance Participatory stakeholder workshops during MDA planning can increase self-reported engagement of key personnel and may improve personnel performance and contribute to achievement of drug coverage targets. Microplanning success was supported by MDA results, with all communes achieving preset MDA coverage targets.
Author summary Lymphatic filariasis is a neglected tropical disease that can be eliminated by treating entire at-risk communities with safe and efficacious medicines, a strategy known as mass drug administration (MDA). MDA campaigns require intense planning to ensure that every eligible person within the community can receive the medicines if they desire. We aimed to improve the campaign by better involving key MDA stakeholders such as volunteers and other important community members in the planning process, through microplanning. The participants suggested many strategies to help the campaign reach more community members, including better ways to prepare and inform that community that the campaign is happening. We invited the microplanning participants to give feedback on how this new strategy worked compared with their experiences during past campaigns. Participants reported that they felt better engaged by health authorities, and in particular, that they had more information about the results of past campaigns, where they should be distributing medicines, and their specific tasks and responsibilities during the campaign. We found that more people received medicines during the campaign that followed the microplanning workshops compared with the previous campaigns. We conclude that microplanning helped to increase the number of people who received MDA medicines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project is covered by a non-research determination granted by the Center for Global Health (CGH) Human Subjects Protection Office at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, USA.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
